$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi, Glaxo Covid shot works as booster, but release pushed back
09:15am, Wednesday, 15'th Dec 2021 Business Standard
Sanofi shares dropped less than 1% in Paris trading, as did Glaxo in London
Global Enzymes Market Size [2021-2028] | is Projected to Reach USD 13,815.2 Million by 2027
08:39am, Wednesday, 15'th Dec 2021 Intrado Digital Media
Key Prominent Players Covered in the Enzymes Market are BASF, Codexis Inc., Amano Enzyme Inc., DSM, Dupont De Nemours & Co., ABF PLC, AB Enzymes, Dyadic International Inc., Advanced Enzyme Technology Ltd., Affymetrix Inc., Bbi Enzymes Ltd., Basf, Codexis Inc., Nagase & Co. Ltd., Life Technologies, Roche Holding Ag., Sanofi S.A. Key Prominent Players Covered in the Enzymes Market are BASF, Codexis Inc., Amano Enzyme Inc., DSM, Dupont De Nemours & Co., ABF PLC, AB Enzymes, Dyadic International Inc., Advanced Enzyme Technology Ltd., Affymetrix Inc., Bbi Enzymes Ltd., Basf, Codexis Inc., Nagase & Co. Ltd., Life Technologies, Roche Holding Ag., Sanofi S.A.
Sanofi - Aventis Groupe: Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
06:41am, Wednesday, 15'th Dec 2021 FinanzNachrichten
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation Positive booster dat
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
06:30am, Wednesday, 15'th Dec 2021 Intrado Digital Media
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
Sanofi, GSK Say Covid Vaccine Works As Booster Shot
05:46am, Wednesday, 15'th Dec 2021
The vaccine's release will be pushed back to 2022 following delays to main clinical trials, the companies said.
GlaxoSmithKline/Sanofi Covid-19 vaccine effective as booster shot, trial shows
04:56am, Wednesday, 15'th Dec 2021
GlaxoSmithKline PLC (LSE:GSK) said the Covid-19 vaccine it is developing with French group Sanofi proved effective as a booster shot in a major independent trial. The vaccine boosted Covid-neutralisin
VanEck Pharmaceutical ETF Buys Sanofi SA, AstraZeneca PLC, AbbVie Inc
04:38am, Wednesday, 15'th Dec 2021 GuruFocus
Related Stocks: SNY , AZN , ABBV , NVS , MRK , VTRS ,
New Jersey, United States,- Verified Market Research has recently published a research report titled, Hereditary Angioedema Treatment Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to
Environment Ministry, Sanofi sign MoU to strengthen bilateral cooperation
10:34pm, Tuesday, 14'th Dec 2021 Daily News Egypt
MoU includes launching competition for environment protection The post Environment Ministry, Sanofi sign MoU to strengthen bilateral cooperation appeared first on Daily News Egypt .
Amgen Petitions for Certiorari to Reconsider Enablement of Genus Claims
09:30pm, Tuesday, 14'th Dec 2021 JD Supra
As we reported earlier this year, Amgen filed a petition for rehearing en banc to the Federal Circuit, arguing that the panel in Amgen v. Sanofi improperly created a new and heightened test for enablement of genus claims with functional limitations. In its earlier decision, the Federal Circuit affirmed the district courts judgment as a matter of law invalidating genus claims in U.S. Patent Nos. 8,829,165 and 8,859,741 that recite functional limitations covering Amgens cholesterol medication By: Kilpatrick Townsend & Stockton LLP
Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients
05:48pm, Tuesday, 14'th Dec 2021 Benzinga
Sanofi SA (NASDAQ: SNY ) presented data from two Phase 3 studies of fitusiran for the prophylactic treatment with hemophilia A or B, with or without inhibitors. Data were shared at the American Society of Hematology (ASH) Annual Meeting. Fitusiran, an RNAi drug designed to silence the gene that overproduces a protein responsible for clotting suppression. Fitusiran cut Full story available on Benzinga.com
Vulvodynia Treatment Drugs Market Expansion Projected to Gain an Uptick During 2021-2027 Covid-19 Analysis | Pfizer, Sanofi Aventis
05:16pm, Tuesday, 14'th Dec 2021 OpenPR
Another exploration Titled "Worldwide Vulvodynia Treatment Drugs 2019-Market Research Report" gives the Professional and inside and out assessment of extent of momentum and future market and survey of Product Specification, showcase pattern , item type and creation investigation considering central
Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH''s plenary and late-breaking ses
Egypt signs MoU with Sanofi to support Go Green Initiative
01:12pm, Tuesday, 14'th Dec 2021 Egypt Independent
Egypt signed a memorandum of understanding for joint cooperation between the Environmental Affairs Agency, represented in the signature by Ali Abu Senna, CEO of the Environmental Affairs Agency, and Sanofi Egypt, which specializes in the pharmaceutical industry, represented by Sherif Omar, Director General of Sanofi Consumer Healthcare in Egypt and Sudan. The agreement aims to … The post Egypt signs MoU with Sanofi to support Go Green Initiative appeared first on Egypt Independent .
Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients
12:48pm, Tuesday, 14'th Dec 2021
Sanofi SA (NASDAQ: SNY) presented data from two Phase 3 studies of fitusiran for the prophylactic treatment with hemophilia A or B, with or without inhibitors. Data were shared at the American Soci
Sign In
Buy SNY